{"filings":[{"id":1111043,"accession_number":"0001628280-26-043869","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2026-06-17T20:05:28+00:00","items":["5.07"],"status":"ready","headline":"Zai Lab shareholders approve all 14 proposals at 2026 AGM; advisory pay vote sees 28% dissent","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All director nominees re-elected; Diekman and Wirth had highest against votes (~39M and ~38M).","Advisory vote on executive compensation approved: 392.7M for, 154.6M against (28% dissent).","General mandates to issue and repurchase up to 10% of shares authorized until 2027 AGM.","KPMG LLP and KPMG ratified as independent auditors for FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584317,"accession_number":"0001628280-26-037387","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2026-05-21T21:18:49+00:00","items":["5.02"],"status":"ready","headline":"Zai Lab President & COO Josh Smiley departs; responsibilities absorbed by CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Josh Smiley ceases as President and COO effective May 18, 2026; last day is May 22, 2026.","CEO Samantha Du and management team assume his responsibilities.","Smiley receives severance under his existing employment agreement subject to release.","No replacement named; Du retains roles as Board Chair, Founder and CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94836,"accession_number":"0001628280-26-031624","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q1 2026 revenue $99.6M (-6% YoY); net loss $51M; zoci shows 62.5% intracranial ORR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $99.6M, down 6% YoY; product revenue $95.6M (-10% YoY); ZEJULA fell to $30M from $49.5M.","Net loss $51M ($0.46/ADS); operating loss $69.4M; cash $761.3M at March 31.","Zoci (DLL3 ADC) delivered 62.5% confirmed intracranial ORR in SCLC brain mets at AACR; 38.2% ORR in epNECs.","Clinical collaborations with Amgen and Boehringer Ingelheim to evaluate zoci combinations in SCLC and NECs.","Appointed Yizhe Wang, Ph.D., as Operating Partner; KarXT launch preparations underway; TIVDAK under regulatory review."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":99611000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107497,"accession_number":"0001704292-26-000014","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q4 total revenue $127.6M (+17% YoY); net loss narrows to $50.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $127.1M (+17% YoY); ZEJULA $56M (+16%), XACDURO $10.7M (+225%).","Net loss Q4 $50.4M (loss per ADS $0.46) vs $81.7M loss Q4 2024; FY loss $175.5M vs $257.1M.","Cash $789.6M as of Dec 31, 2025; R&D expenses $61.6M Q4 (+18% YoY).","KarXT approved in China Dec 2025; commercial launch H1 2026; NRDL renewals for VYVGART, NUZYRA, ZEJULA.","Global pipeline: zoci (DLL3 ADC) advancing to three registration-enabling studies; ZL-1503 Phase 1 data H2 2026; ZL-1311 IND by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":460156000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123850,"accession_number":"0001704292-25-000023","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q3 revenue up 14% to $116.1M; loss narrows; revises FY2025 guidance to at least $460M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $115.4M (+13% YoY); VYVGART $27.7M, ZEJULA $42.4M, NUZYRA $15.4M.","Operating loss improved 28% YoY to $48.8M GAAP; adjusted operating loss $28.0M (-42% YoY).","Net loss $36.0M ($0.33/ADS) vs $41.7M ($0.42/ADS) in Q3 2024.","Global registrational study for zoci (DLL3 ADC) initiated; Phase 1 data showed 68% ORR at 1.6 mg/kg in 2L+ ES-SCLC.","Cash $817.2M; FY2025 revenue guidance revised to at least $460M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":332559000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123849,"accession_number":"0001704292-25-000014","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zai Lab secures RMB300M ($42.1M) revolving credit facility from Industrial Bank for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Guarantee and credit line contract with Industrial Bank for up to RMB300M (~$42.1M) to Zai Lab Shanghai.","Facility available until May 5, 2026; each loan expected one-year term.","No loans drawn to date; facility for working capital in mainland China.","Contains customary covenants including prior consent for certain transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140515,"accession_number":"0001628280-25-038547","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q2 revenue grows 9% YoY to $110M; operating loss improves 28%; targets Q4 profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $109.1M (+9% YoY); VYVGART sales $26.5M (+46% QoQ); ZEJULA $41.0M (down from $45M YoY).","GAAP operating loss $54.9M (improved 28% YoY); adjusted operating loss $34.2M (improved 37% YoY).","Net loss $40.7M vs $80.3M YoY; cash $832.3M as of June 30, 2025.","Reaffirms FY2025 revenue guidance $560M-$590M; on track for adjusted profitability in Q4 2025.","Pipeline: ZL-1310 ORR 79% at 1.6mg/kg in 2L ES-SCLC; bemarituzumab Phase 3 met OS endpoint; China submission H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":216464000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.77,"calibrated_materiality_score":0.77,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158218,"accession_number":"0001628280-25-032099","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zai Lab shareholders approve all 14 proposals at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All director nominees re-elected, including Samantha Du, John Diekman, Richard Gaynor, Nisa Leung, William Lis, Scott Morrison, Leon Moulder, Michel Vounatsos, and Peter Wirth.","Ratification of KPMG as independent auditor for FY2025 approved (794,030,890 for).","Advisory say-on-pay for named executive officers passed with 636,374,843 votes for.","General mandates to allot/issue up to 10% of shares and to repurchase up to 10% of shares both approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158217,"accession_number":"0001628280-25-023410","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q1 revenue up 22% to $106.5M; operating loss narrows 20%; on track for Q4 profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $105.7M (+21% YoY); VYVGART $18.1M, ZEJULA $49.5M, NUZYRA $15.1M.","Adjusted operating loss $37.1M, improved 25% YoY; net loss $48.4M vs $53.5M prior year.","Cash $857.3M; reaffirms FY2025 revenue guidance $560M-$590M.","ZL-1310 (DLL3 ADC) pivotal study in ES-SCLC expected H2 2025; ASCO data June 2.","Discontinued ZL-1102 (IL-17) Phase 2 trial after interim analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":106487000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176580,"accession_number":"0001628280-25-008406","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q4 2024 revenue $109.1M (+66% YoY); guides FY2025 revenue $560-590M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $399.0M for FY2024, up 50% YoY; product revenue $397.6M, up 49% YoY.","VYVGART franchise net revenue $93.6M in first full year; ZEJULA $187.1M (+11% YoY); NUZYRA $43.2M (+99% YoY).","Loss from operations decreased 23% to $282.1M for FY2024; net loss per ADS $2.60 vs $3.46 in 2023.","Cash position $879.7M as of Dec 31, 2024; expects adjusted profitability (non-GAAP) in Q4 2025.","ZL-1310 (DLL3 ADC) SCLC trial showed 74% ORR; NDA accepted for KarXT in schizophrenia in China."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":398988000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176579,"accession_number":"0001628280-25-000261","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zai Lab secures RMB300M ($41.1M) revolving credit facility from Bank of Communications","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Guarantee and loan contract signed Jan 2, 2025 with BOCOM for working capital loans to subsidiary Zai Lab Shanghai.","Facility available until Sep 26, 2025; each loan term up to 12 months, maturity no later than Mar 26, 2026.","Interest rate set at one-year LPR minus 35 bps, adjusted quarterly.","Covenants include BOCOM consent for M&A, equity transfers, or debt financing exceeding RMB1.5B (~$205.5M).","No working capital loans drawn under the facility as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193432,"accession_number":"0001193125-24-259957","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Zai Lab prices $200M ADS offering at $25.50 per ADS; net proceeds ~$189M for general corporate purposes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 7,843,137 ADSs at $25.50 per ADS; expected gross proceeds ~$200M.","Net proceeds after underwriting discounts and expenses expected ~$189M; closing on or about Nov 18, 2024.","Underwriters granted 30-day option to purchase up to 1,176,470 additional ADSs at offering price.","Proceeds to be used for general corporate purposes; offering made under effective shelf registration S-3ASR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193431,"accession_number":"0001628280-24-047588","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zai Lab updates risks: employee medical fraud probes in China, Optune patent setbacks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Several current/former employees in ZEJULA sales team under criminal investigation by Chinese authorities for alleged medical insurance fraud; individuals detained or under compulsory measures.","Two Chinese patents covering Optune were successfully invalidated; decision on appeal. Optune-related patents expected to expire within two years.","Company warns of material adverse effects from data privacy non-compliance, anti-corruption investigations (including FCPA), and licensing disputes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193430,"accession_number":"0001628280-24-046809","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q3 net product revenue rises 47% YoY to $101.8M; KarXT bridging study positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $101.8M, up 47% YoY; net loss $41.7M ($0.42/ADS loss).","VYVGART sales $27.3M (vs $4.9M YoY); ZEJULA $48.2M (+16%); NUZYRA $10.0M (+82%).","KarXT bridging study in schizophrenia met primary endpoint (9.2-point PANSS reduction, p=0.0014); NDA submission expected early 2025.","ZL-1310 (DLL3 ADC) Phase 1 data shows 74% ORR in extensive-stage SCLC; potential best-in-class.","Cash position $716.1M; three product launches in China expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":289918000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209751,"accession_number":"0001628280-24-035194","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q2 net product revenue $100.1M (+45% YoY); narrows net loss to $80.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $100.1M, up 45% YoY (47% at CER); VYVGART contributed $23.2M vs $0.1M YoY.","Net loss $80.3M ($0.82/ADS loss), improved from $120.9M loss ($1.25/ADS) in Q2 2023.","Raises full-year VYVGART revenue guidance to exceed $80.0M; cash position $730.0M as of June 30.","Three NMPA product approvals: XACDURO (HABP/VABP), efgartigimod SC (gMG), AUGTYRO (ROS1+ NSCLC).","Expanded global oncology pipeline with next-gen ROR1 ADC (ZL-6301) via MabCare partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":187653000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209750,"accession_number":"0001628280-24-031485","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zai Lab secures RMB250M credit facility from China Merchants Bank for subsidiary working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Parent company issued guarantee to China Merchants Bank (Shanghai) for loans up to RMB250M (~$34.4M) for wholly owned subsidiary Zai Lab Shanghai.","Credit facility is for one year; specific loan terms will be in separate transaction documents.","No working capital loans have been drawn under the facility as of the filing date.","Facility supports working capital needs in mainland China; includes customary covenants requiring prior bank consent for certain transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227926,"accession_number":"0001628280-24-028764","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Zai Lab shareholders approve 2024 equity plan, re-elect all directors at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Equity Incentive Plan approved (568.4M for, 215.2M against), replacing 2022 Plan with more shares.","All 10 director nominees re-elected, including Samantha Du and Leon Moulder Jr.","Advisory vote on named executive officer compensation passed (530.4M for, 253.2M against).","General mandate to issue up to 20% of shares (for allotment) and repurchase mandate up to 10% approved.","KPMG ratified as auditor for FY2024 (783.6M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227925,"accession_number":"0001628280-24-027668","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zai Lab CMO Dr. Harald Reinhart to retire; Dr. Rafael Amado to lead all Global R&D","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Harald Reinhart, President, Head of Global Development (NSAiID), retiring effective June 30, 2024.","Reinhart will remain as a senior advisor; no disagreements led to his retirement.","Dr. Rafael Amado expands role to President, Head of Global R&D upon Reinhart's retirement.","Amado previously President of Global Oncology R&D; now oversees all therapy areas.","CEO Samantha Du noted Reinhart built strong NSAiID team for continued growth under Amado."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227924,"accession_number":"0001628280-24-021674","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q1 product revenue $87.1M (+39% YoY); net loss $53.5M, VYVGART sales $13.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $87.1M (+39% YoY; +43% at CER); ZEJULA $45.5M (+7%), VYVGART $13.2M (launch Sep 2023).","Net loss $53.5M ($0.55 loss per ADS) vs $49.1M in Q1 2023; R&D $54.6M, SG&A $69.2M.","Cash $750.8M at Mar 31, 2024, down from $806.5M at Dec 31, 2023.","Appointed Andrew Zhu as Chief Commercial Officer for Greater China in April 2024.","Regulatory milestones: sBLA submitted for efgartigimod SC in CIDP; potential NMPA approvals for repotrectinib, sulbactam-durlobactam, efgartigimod SC in gMG in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":87149000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246694,"accession_number":"0001628280-24-007217","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab FY2023 product revenue $266.7M (+25% YoY); VYVGART launch drives 2024 outlook >$70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $266.7M (+25% YoY; +31% CER); net loss narrowed to $334.6M from $443.3M.","VYVGART launched Sept 2023; 2023 revenue $10M; ~1,000 patients treated in Jan 2024; 2024 guidance >$70M.","ZEJULA $168.8M (+16% YoY); OPTUNE $47.0M (flat); QINLOCK $19.2M (+29%); NUZYRA $21.7M (+316%).","Cash $807.6M (Dec 31, 2023) vs $1.0B year prior; R&D down, SG&A up on VYVGART launch.","Targeting profitability by end of 2025; regulatory submissions expected for 4 new products in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":266719000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246693,"accession_number":"0001628280-24-003902","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zai Lab enters debt facilities with three Chinese banks for up to ~$174M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["BOC HK facility: $100M uncommitted, one-year term; $50M standby L/C issued; Zai Lab Shanghai draws RMB340M (~$47.8M) loan at ~2.95%.","SPD Bank guarantee for up to RMB300M (~$42M) over three years; no loans drawn yet.","Ningbo Bank max credit of RMB230.3M (~$32.4M); no drawdowns; Zai Lab Suzhou to pledge real property.","Proceeds used for working capital in China; company says it provides enhanced flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264124,"accession_number":"0001628280-23-037353","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q3 revenue $69.2M (+22% YoY); launches VYVGART in China, net loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $69.2M, up 22% YoY; VYVGART contributed $4.9M since September launch.","Net loss $69.2M vs $161.2M in Q3 2022; R&D expenses fell to $58.8M from $99.5M.","Cash $822.2M at Sept 30, down from $876.4M at June 30, 2023.","Terminated ZL-1211 (Claudin18.2) development; appointed Dr. Robert Brown as CMO, Oncology.","Expects at least seven product launches in 2-3 years; multiple NDAs under review (repotrectinib, odronextamab)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":200889000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281372,"accession_number":"0001628280-23-027767","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q2 product rev $68.9M (+45% YoY); VYVGART approved in China; net loss $120.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $68.9M, up 45% YoY (53% constant currency); driven by ZEJULA $43.0M, Optune $13.7M.","Net loss $120.9M ($0.13 loss per ADS) vs $137.9M loss a year ago; R&D spend $76.7M, SG&A $67.9M.","Cash $876.4M as of June 30, 2023; down from $931.4M at March 31, 2023.","NMPA approved VYVGART (efgartigimod) for gMG; launch preparation underway; NRDL listing eligible for 2024.","Promoted Yajing Chen to CFO effective July 7, 2023; targeting corporate profitability by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":131661000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281371,"accession_number":"0001628280-23-024454","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zai Lab promotes Yajing Chen to CFO, replacing Billy Cho effective July 7","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yajing Chen promoted to CFO effective July 7, 2023; she was previously Deputy CFO.","William Cho steps down to pursue private equity opportunity; no disagreements with Company.","Chen receives $450,000 base salary, 40% target bonus, option for 20,000 ADSs, and 5,000 RSUs.","Cho gets pro-rated bonus, low six-figure severance, and continued RSU vesting through July 2024 with a three-month trading lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300169,"accession_number":"0001628280-23-024042","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"China NMPA approves Zai Lab's VYVGART for generalized myasthenia gravis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NMPA approved VYVGART (efgartigimod alfa) as add-on for anti-AChR+ gMG adults.","Phase 3 ADAPT: 68% responders on MG-ADL vs 30% placebo (p<0.0001) in first cycle.","Zai Lab to seek National Reimbursement Drug List inclusion for broader patient access.","Zai Lab holds exclusive license from argenx to develop/commercialize in mainland China, HK, Macau, Taiwan.","VYVGART is the first approved FcRn antagonist for gMG in China; ~200,000 MG patients in country."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300168,"accession_number":"0001628280-23-022683","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zai Lab 2023 AGM: directors re-elected, share mandate approved, exec compensation passes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All director nominees re-elected except Michel Vounatsos (elected as new director); each with >85% support.","Advisory vote on executive compensation passed with 528.4M for, 332.8M against (~38.6% opposition).","Share issuance mandate (up to 20% of shares) approved narrowly: 445.6M for vs 415.6M against (51.7% for).","Proposal to fix auditor compensation and appointment of KPMG as auditor for FY 2023 approved with near-unanimity.","Proposal 15 (alternative 10% mandate) dropped because Proposal 14 passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300167,"accession_number":"0001628280-23-021025","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zai Lab partner Novocure's LUNAR Phase 3 trial meets endpoint, shows 3-month OS improvement in metastatic NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TTFields + standard therapies improved median OS from 9.9 to 13.2 months (HR 0.74, p=0.035) in post-platinum metastatic NSCLC.","ICI subgroup median OS was 18.5 vs 10.8 months (HR 0.63, p=0.03), an 8-month improvement.","TTFields was well-tolerated with no added systemic toxicities; only grade 3 device-related AEs.","Novocure plans PMA submission to FDA in H2 2023; Zai Lab will file MAA to China's NMPA thereafter.","Zai Lab has exclusive license to develop/commercialize TTFields in Greater China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300166,"accession_number":"0001628280-23-016803","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q1 product revenue $62.8M, up 36% YoY; net loss narrows to $49.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $62.8M (+36% YoY); ZEJULA $42.7M (+44% YoY); Optune $13.3M; QINLOCK $1.3M; NUZYRA $5.5M.","Net loss $49.1M ($0.05 per share) vs $82.4M loss ($0.09 per share) in Q1 2022.","Cash $931.4M at March 31, 2023; R&D expense $48.5M, SG&A $62.5M.","Josh Smiley promoted to President and COO effective April 1, 2023.","Entered global license with MediLink for DLL3 ADC (ZL-1310) to expand lung cancer and oncology pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":62797000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320225,"accession_number":"0001628280-23-010007","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Zai Lab reports temporary HKEX trading suspension resolved same day after publishing annual results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trading in Zai Lab shares on HKEX suspended at 9:06 a.m. on March 31, 2023 pending publication of annual results.","Annual results published at 12:38 p.m. same day; suspension ended at 1:00 p.m.","Financial information in annual results consistent with previously filed 10-K (March 1, 2023); suspension not related to business conduct or results substance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320224,"accession_number":"0001628280-23-005822","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Reports Full-Year 2022 Revenue of $215M, Up 49% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $215.0M in 2022, a 49.0% increase year-over-year; ZEJULA revenue $145.2M, up 55.2%.","Net loss narrowed to $443.3M from $704.5M in 2021; cash position $1.0B as of Dec 31, 2022.","Expects commercial profitability in 2023 and overall corporate profitability by end of 2025.","Key pipeline milestones: BLA submission for efgartigimod in gMG, NDA for repotrectinib, and initiation of KarXT bridging study in China.","Appointed Michel Vounatsos to Board and Rafael Amado as President, Global Oncology R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":215040000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320223,"accession_number":"0001628280-23-000722","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zai Lab appoints former Biogen CEO Michel Vounatsos as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Michel Vounatsos independent director effective Jan 7, 2023; chairs Commercial Committee and serves on R&D.","Vounatsos was Biogen CEO (2017-2022) and previously President of MSD China; brings global and China commercial expertise.","Compensation: $50k annual retainer, $15k for Commercial chair, $7.5k for R&D; restricted shares $750k vesting over 3 years.","Press release notes Zai Lab has four marketed medicines and plans three more launches in near term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320222,"accession_number":"0001628280-23-000450","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zai Lab partner Novocure's LUNAR study meets primary overall survival endpoint in stage 4 NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LUNAR study showed statistically significant and clinically meaningful improvement in overall survival vs standard therapies alone.","TTFields + immune checkpoint inhibitors demonstrated significant OS benefit; positive trend with TTFields + docetaxel.","Zai Lab has exclusive license to develop and commercialize TTFields in mainland China, Hong Kong, Macau, and Taiwan.","Novocure plans to file PMA with FDA and CE Mark in EU in H2 2023; full results at future medical congress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338365,"accession_number":"0001628280-22-029232","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q3 revenue $57.5M (+33% YoY); net loss widens to $161.2M on Seagen payment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $57.5M vs $43.1M YoY; net product revenue led by ZEJULA $39.2M.","Net loss $161.2M vs $96.4M YoY, reflecting $30M upfront to Seagen and $36.7M FX loss.","Cash & equivalents $1.12B; company expects runway through 2025.","Entered collaboration with Seagen for TIVDAK in Greater China.","Appointed Dr. Peter Huang as CSO and Alette Verbeek as SVP Global Strategic Partnering."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":152439000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338364,"accession_number":"0001628280-22-027328","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zai Lab officer Alan Sandler resigns effective Oct 28, 2022; severance agreement signed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Alan Sandler resigns effective October 28, 2022 to pursue another professional opportunity.","No disagreements between Sandler and Company regarding operations, policies, or practices.","Severance includes annual base salary, pro-rated bonus, and a low six-figure additional payment.","Sandler contributed to oncology programs, long-term strategy, and business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355729,"accession_number":"0001628280-22-025522","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-09-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Zai Lab licenses TIVDAK from Seagen for China, HK, Macau, Taiwan; $30M upfront plus milestones up to $263M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Zai Lab pays $30M upfront, up to $78M in dev/reg milestones, and up to $185M in sales milestones.","Seagen receives tiered royalties from mid-teens to low twenties on net sales in licensed territory.","Payments shared 50/50 with Genmab under existing Seagen/Genmab co-development agreement.","TIVDAK is FDA-approved for recurrent/metastatic cervical cancer; Phase 3 trial (innovaTV 301) ongoing.","Approximately 110,000 new cervical cancer cases annually in China, representing significant unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355728,"accession_number":"0001628280-22-021960","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q2 2022 revenue $48.2M (+31% YoY); net loss narrows; efgartigimod BLA accepted in China","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $48.2M (Q2 2021: $36.9M); ZEJULA revenue $34.1M (+46% YoY). Net loss $137.9M vs $163.3M.","Cash position $1.26B; NMPA accepted BLA for efgartigimod in generalized myasthenia gravis.","Karuna's KarXT Phase 3 EMERGENT-2 met primary endpoint: 9.6-point PANSS reduction vs placebo (p<0.0001).","Josh Smiley appointed COO effective Aug 1; John Diekman named Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":94900000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355727,"accession_number":"0001193125-22-211271","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zai Lab appoints Joshua Smiley as COO, effective August 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joshua Smiley appointed COO; previously Eli Lilly SVP and CFO since 1995.","Annual base salary of $600,000; target annual bonus of 50% of base.","Cash sign-on bonus of $400,000: $250,000 in Aug 2022 and $150,000 in Aug 2023 contingent on Boston relocation.","Grant of option for 139,000 ADSs and RSUs for 79,500 ADSs, vesting annually over five years.","Entered into employment agreement and standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373997,"accession_number":"0001193125-22-178758","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Zai Lab shareholders approve 2022 Equity Plan and amended Articles for HK dual-primary listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 2022 Equity Incentive Plan (97,908,743 shares) conditioned on HKEX dual-primary listing becoming effective.","Sixth Amended and Restated Memorandum and Articles of Association approved to reflect HK listing requirements and March 2022 share subdivision.","All twelve director nominees re-elected, including CEO Samantha Du and chairs; advisory vote on exec compensation set for annual frequency.","Ratification of KPMG LLP as independent auditor for FY2022; share issue mandate of up to 20% of issued shares approved.","Plan replaces 2017 and 2015 plans; no new grants under old plans after HK dual-primary listing effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373992,"accession_number":"0001193125-22-164558","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K/A","filed_at":"2022-06-01T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Zai Lab appoints KPMG as new auditor; dismisses Deloitte effective May 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KPMG LLP engaged as independent registered public accounting firm for FY2022, effective May 31, 2022.","Deloitte dismissed after completing Q1 2022 10-Q services; dismissal effective upon regulatory approvals.","No disagreements or reportable events with Deloitte during fiscal years 2020 and 2021.","Deloitte's reports on FY2020 and FY2021 financials were unqualified with no adverse opinions.","Deloitte provided a letter to the SEC agreeing with the disclosures in this 8-K/A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373996,"accession_number":"0001193125-22-163153","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zai Lab receives HKSE acknowledgement for dual-primary listing effective June 27, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HKSE acknowledged Zai Lab's application for voluntary conversion from secondary to dual-primary listing.","Dual-primary listing on HKSE and Nasdaq expected effective June 27, 2022; stock marker 'S' to be removed.","Company to adopt new 2022 equity incentive plan compliant with HK Listing Rules, subject to June 22 AGM vote.","Waivers sought from HKSE for U.S. GAAP financials and option exercise price based on ADS price.","Primary conversion aims to broaden investor base in Greater China and increase liquidity of securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373995,"accession_number":"0001193125-22-146289","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab Q1 2022 results; excerpts lack financials; auditor, share split, COO announced","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Announced Q1 2022 financial results on May 10, 2022; specific revenue and earnings figures not visible in the provided excerpt.","Engaged KPMG as independent auditor for FY2022, replacing prior auditor, to comply with PCAOB inspection and Nasdaq listing requirements.","Shareholders approved 1-for-10 ordinary share subdivision effective March 30, 2022, aimed at increasing liquidity and lowering trading price.","Appointed Josh Smiley as COO effective August 2022; he brings over 26 years of biopharmaceutical industry experience."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":46724000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373991,"accession_number":"0001193125-22-136847","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K/A","filed_at":"2022-05-02T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Zai Lab dismisses Deloitte, appoints KPMG as auditor for FY2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved engagement of KPMG LLP for FY2022 SEC and HK Stock Exchange filings, subject to regulatory approvals.","Dismissal of Deloitte effective after completion of Q1 2022 Form 10-Q and receipt of HK approvals for KPMG.","No disagreements or reportable events with Deloitte; their 2020 and 2021 reports were unqualified.","Deloitte provided a letter to the SEC agreeing with the company's disclosures regarding the dismissal.","Press release dated April 21, 2022 announced the auditor change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373994,"accession_number":"0001193125-22-112107","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Zai Lab engages KPMG as US auditor to comply with HFCAA and maintain Nasdaq listing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Engaged KPMG LLP as independent auditor for FY2022, replacing Deloitte.","KPMG is subject to PCAOB inspection, expected to facilitate compliance with Holding Foreign Companies Accountable Act.","No disagreements or reportable events with Deloitte; dismissal effective after Q1 2022 Form 10-Q and regulatory approvals.","Transition supports continued Nasdaq listing and global shareholder base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373993,"accession_number":"0001193125-22-093727","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zai Lab CSO Tao Fu resigns effective April 8, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tao Fu, Chief Strategy Officer, notified Zai Lab of resignation on March 28, 2022.","Resignation effective at close of business on April 8, 2022.","No disagreements with Company regarding operations, policies or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392624,"accession_number":"0001193125-22-086628","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-03-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zai Lab shareholders approve 10-for-1 share subdivision effective March 30, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subdivision approved by 82,350,538 votes for vs 21,786 against and 5,788 abstentions.","Each existing ordinary share (US$0.00006 par) becomes 10 shares (US$0.000006 par).","Authorized shares increased from 500M to 5B; total par value unchanged at US$30,000.","Effective March 30, 2022, subject to HK Listing Committee granting listing permission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392623,"accession_number":"0001193125-22-075434","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zai Lab appoints Joshua Smiley as COO effective August 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joshua Smiley appointed Chief Operating Officer, effective August 1, 2022, reporting to CEO Samantha Du.","Smiley brings 26 years biopharma experience, most recently as SVP and CFO at Eli Lilly.","He will oversee business, finance, and global operations; based in Cambridge, Massachusetts.","CEO Dr. Du said Smiley will be instrumental in expanding geographies and diversifying financial footprint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392622,"accession_number":"0001193125-22-061344","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zai Lab reports FY2021 results; financial details not provided in 8-K exhibit","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Announced financial results for FY2021; specific revenue and EPS figures not provided in the filing.","Forecasts peak-year sales from lung and GI cancer franchises could reach $2.5–3B by 2030.","Proposed share subdivision of ordinary shares (1:10) to increase liquidity on HKEX; shareholder vote sought.","Plans to submit NDA for efgartigimod in gMG in China in mid-2022; multiple clinical milestones.","Entered license agreements for KarXT (neuroscience) and BLU-945/701 (EGFR NSCLC) in Greater China."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":144312000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392621,"accession_number":"0001193125-22-003149","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2022-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zai Lab's NDA for margetuximab accepted by China NMPA for HER2+ breast cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NMPA accepted NDA for margetuximab, a HER2-targeted monoclonal antibody, for metastatic HER2+ breast cancer with 2+ prior anti-HER2 therapies.","Margetuximab is the only HER2-targeted agent to show PFS improvement vs trastuzumab in head-to-head Phase 3 SOPHIA trial.","NDA acceptance marks Zai Lab's sixth NDA acceptance by NMPA and expands women's oncology franchise.","Bridging study in Chinese patients met primary endpoint of PFS by BICR; safety consistent with SOPHIA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410995,"accession_number":"0001193125-21-364991","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2021-12-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zai Lab promotes Harald Reinhart to President and Head of Global Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Harald Reinhart, M.D., promoted from CMO to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases","Reinhart received a special equity grant of 30,000 restricted share units, with 50% vesting immediately and 50% on Dec 31, 2022","Base salary and target bonus for 2022 and 2021 bonus increased to be commensurate with other executive officers","Reinhart has been with Zai Lab since inception, first as advisor and since 2017 as CMO","Prior to Zai Lab, he served at Shionogi U.S., Novartis, and Bayer Corp with broad clinical development experience"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410994,"accession_number":"0001193125-21-358580","cik":1704292,"company_name":"Zai Lab Ltd","ticker":"ZLAB","form_type":"8-K","filed_at":"2021-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NMPA approves Zai Lab's NUZYRA as Category 1 innovative drug for CABP and ABSSSI","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NMPA approved NUZYRA (omadacycline) for community-acquired bacterial pneumonia and acute bacterial skin infections.","Approved as Category 1 innovative drug; locally manufactured in China; Zai Lab's fourth product approval in 24 months.","NUZYRA offers IV and oral formulations, targeting multi-drug-resistant bacteria; first Zai Lab product outside oncology.","Approval based on three Phase 3 studies in Chinese patients; NUZYRA previously FDA-approved and marketed by Paratek in US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16208689137.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-16T23:59:59+00:00|410994"}